GNI Hong Kong Ltd - 27 Oct 2023 Form 4 Insider Report for CATALYST BIOSCIENCES, INC. (GYRE)

Role
10%+ Owner
Signature
/s/ Branden Berns, as attorney-in-fact for GNI Hong Kong Ltd
Issuer symbol
GYRE
Transactions as of
27 Oct 2023
Net transactions value
$0
Form type
4
Filing time
27 Oct 2023, 19:56:00 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBIO Common Stock Other -5,371,304 -100% 0 27 Oct 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBIO Series X Convertible Preferred Stock Other -10,577 -100% 0 27 Oct 2023 Common Stock 105,770,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

GNI Hong Kong Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376.
F2 Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).